Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · 8-K

RespireRx Pharmaceuticals Inc.

Current Report

Filed Sep 6, 2024Accepted Sep 6, 2024, 4:45 AM EDTCIK 849636Accession 0001493152-24-035221
Share

Company context

Historical securities (2)

Recent company filings

  1. REVOKED filingNov 14, 2025
  2. Regulation FD DisclosureFeb 10, 2025
  3. 8-K filingAug 2, 2024
  4. 8-K filingJul 8, 2024
  5. 8-K filingMay 29, 2024